BRISBANE, Calif., Nov. 17, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced that Peter Maag, Chief Executive Officer, and Ken Ludlum, Chief Financial Officer, will be participating in two upcoming investor conferences.
CareDx management will be presenting at the 27th Annual Piper Jaffray Healthcare Conference in New York City on December 1, 2015 at 1:30pm PT/4:30pm ET. A live audio webcast of the presentation will be available online from the Investor Relations page of the Company's website at http://investors.caredxinc.com. The webcast replay of the presentation will begin approximately one hour after the conclusion of the live presentation and will be available on the Company's website for 90 days.
CareDx management is also scheduled to participate in the Evercore ISI MedTools Investor Conference in Boston, MA on December 3, 2015.
About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next-generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. For more information, please visit: www.CareDx.com.